The Melbourne-based company announced it analyzed sleep data from 80 participants over 3,200 nights in randomized controlled trials and found positive sleep responses to LSD microdosing treatment.
The initial sleep data results included recording, measuring and analyzing sleep patterns in both the LSD microdosing treatment group and the placebo group.
“The sleep data holds promise for a potential tolerable alternative to sleeping pills,” said MindBio CEO and co-founder Justin Hanka.
“We are rigorously pursuing masses of LSD microdosing data under randomized controlled conditions to obtain the evidence we need to expedite approvals for access to this medicine to effectively treat mood and sleep disorders.”
MindBio is preparing seven research papers analyzing this Phase 1 data involving 80 healthy subjects. These documents will form the basis for the launch of two fully funded Phase 2 LSD microdosing clinical trials.
The first study will focus on major depressive disorder, with 20 patients undergoing an eight-week LSD microdosing treatment regimen in a natural home setting.
The second study will explore the effectiveness of microdosing LSD in combination with meaning-centered psychotherapy for late-stage cancer patients experiencing emotional distress.
The findings are particularly significant for depression and related mental health conditions, according to MindBio researchers.
Current treatments for mood and sleep disorders often involve a combination of antidepressants and sleeping pills, which carry risks and unwanted side effects.
(Natalia Buendia Clavillo her Mugglehead of 06/16/2023)
the association does not receives and is against public funding (also 5 per thousand)
Its economic strength are inscriptions and contributions donated by those who deem it useful
DONATE NOW